Subscribe
alessandro-zappalorto
Alessandro Zappalorto / Shutterstock.com
8 April 2020Big PharmaRory O'Neill

EMA unveils fast-track drug shortage monitoring

The EU’s drugs regulator has set up a fast-track system to monitor shortages during the COVID-19 pandemic.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
EMA backs switch to biosimilars
22 September 2022   Evidence shows medicines approved as biosimilars in the EU may be prescribed interchangeably | Additional ‘switch’ studies no longer not need to be carried out.
Big Pharma
Report slams big pharma influence in EU-funded project
28 May 2020   A new NGO report has sharply criticised the EU-funded Innovative Medicines Initiative as favouring Big Pharma over small businesses, particularly when it comes to IP.


Editor's picks

Smart ringleader: Could Ōura’s market dominance be under threat?
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025

Editor's picks

Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025
Europe
Four firms reach highest tier in WIPR’s 2025 Global Trade Secrets Rankings
18 August 2025
Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025

More on this story

Biotechnology
EMA backs switch to biosimilars
22 September 2022   Evidence shows medicines approved as biosimilars in the EU may be prescribed interchangeably | Additional ‘switch’ studies no longer not need to be carried out.
Big Pharma
Report slams big pharma influence in EU-funded project
28 May 2020   A new NGO report has sharply criticised the EU-funded Innovative Medicines Initiative as favouring Big Pharma over small businesses, particularly when it comes to IP.

More on this story

Biotechnology
EMA backs switch to biosimilars
22 September 2022   Evidence shows medicines approved as biosimilars in the EU may be prescribed interchangeably | Additional ‘switch’ studies no longer not need to be carried out.
Big Pharma
Report slams big pharma influence in EU-funded project
28 May 2020   A new NGO report has sharply criticised the EU-funded Innovative Medicines Initiative as favouring Big Pharma over small businesses, particularly when it comes to IP.

More features

GSK escalates mRNA COVID-19 vaccine dispute
Smart ringleader: Could Ōura’s market dominance be under threat?
The flaw that landed Sanofi a win in the rare disease space
Roche resolves cancer test dispute with Stanford affiliated startup
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
UK firm expands in Germany with more litigation hires
Sandoz blocked by UK court from seeking Xarelto profits
An update on patenting in Ukraine, Russia and Eurasia